ProPhase Labs, Inc. Deferred Tax Assets, Tax Credit Carryforwards
ProPhase Labs, Inc. (PRPH) had Deferred Tax Assets, Tax Credit Carryforwards of $0 as of 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Credit Carryforwards
us-gaap:DeferredTaxAssetsTaxCreditCarryforwards · last filed 2026-06-01
- 2025-12-31: Deferred Tax Assets, Tax Credit Carryforwards $0.00.
- 2024-12-31: Deferred Tax Assets, Tax Credit Carryforwards $350.00K.
- 2023-12-31: Deferred Tax Assets, Tax Credit Carryforwards $350.00K.
- 2022-12-31: Deferred Tax Assets, Tax Credit Carryforwards $0.00.
| Period end | Deferred Tax Assets, Tax Credit Carryforwards |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-06-01 |
| 2024-12-31 | $350.00K 10-K · filed 2026-06-01 |
| 2023-12-31 | $350.00K 10-K · filed 2025-04-01 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |